KR20000060771A - 안정화된 효소 또는 단백질을 제조하는 방법 및 이에 의해 제공되는 안정화 효소 또는 단백질을 함유하는 외용제 조성물 - Google Patents
안정화된 효소 또는 단백질을 제조하는 방법 및 이에 의해 제공되는 안정화 효소 또는 단백질을 함유하는 외용제 조성물 Download PDFInfo
- Publication number
- KR20000060771A KR20000060771A KR1019990009380A KR19990009380A KR20000060771A KR 20000060771 A KR20000060771 A KR 20000060771A KR 1019990009380 A KR1019990009380 A KR 1019990009380A KR 19990009380 A KR19990009380 A KR 19990009380A KR 20000060771 A KR20000060771 A KR 20000060771A
- Authority
- KR
- South Korea
- Prior art keywords
- enzyme
- protein
- glucan
- beta
- solution
- Prior art date
Links
- 102000004190 Enzymes Human genes 0.000 title claims abstract description 83
- 108090000790 Enzymes Proteins 0.000 title claims abstract description 83
- 239000000203 mixture Substances 0.000 title claims abstract description 62
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 57
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 57
- 238000000034 method Methods 0.000 title claims abstract description 51
- 230000000087 stabilizing effect Effects 0.000 title claims abstract description 14
- 238000002360 preparation method Methods 0.000 claims abstract description 50
- 229920001503 Glucan Polymers 0.000 claims abstract description 34
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 claims abstract description 18
- 229920002305 Schizophyllan Polymers 0.000 claims abstract description 13
- 229920002498 Beta-glucan Polymers 0.000 claims abstract description 10
- WDQLRUYAYXDIFW-RWKIJVEZSA-N (2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-4-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound O[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O1 WDQLRUYAYXDIFW-RWKIJVEZSA-N 0.000 claims abstract description 7
- FEBUJFMRSBAMES-UHFFFAOYSA-N 2-[(2-{[3,5-dihydroxy-2-(hydroxymethyl)-6-phosphanyloxan-4-yl]oxy}-3,5-dihydroxy-6-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-4-yl)oxy]-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl phosphinite Chemical compound OC1C(O)C(O)C(CO)OC1OCC1C(O)C(OC2C(C(OP)C(O)C(CO)O2)O)C(O)C(OC2C(C(CO)OC(P)C2O)O)O1 FEBUJFMRSBAMES-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000003381 stabilizer Substances 0.000 claims abstract description 6
- 239000003638 chemical reducing agent Substances 0.000 claims abstract description 5
- 229920001491 Lentinan Polymers 0.000 claims abstract description 3
- 229940115286 lentinan Drugs 0.000 claims abstract description 3
- 238000005406 washing Methods 0.000 claims abstract description 3
- 229940088598 enzyme Drugs 0.000 claims description 80
- 235000018102 proteins Nutrition 0.000 claims description 51
- 238000009472 formulation Methods 0.000 claims description 38
- 239000004365 Protease Substances 0.000 claims description 34
- 229940055729 papain Drugs 0.000 claims description 22
- 108090000526 Papain Proteins 0.000 claims description 20
- 235000019834 papain Nutrition 0.000 claims description 20
- 239000004325 lysozyme Substances 0.000 claims description 19
- 229960000274 lysozyme Drugs 0.000 claims description 19
- 235000000346 sugar Nutrition 0.000 claims description 14
- 108010014251 Muramidase Proteins 0.000 claims description 13
- 102000016943 Muramidase Human genes 0.000 claims description 13
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims description 13
- 239000003102 growth factor Substances 0.000 claims description 13
- 235000010335 lysozyme Nutrition 0.000 claims description 13
- 108091005804 Peptidases Proteins 0.000 claims description 10
- 239000002537 cosmetic Substances 0.000 claims description 10
- 239000006071 cream Substances 0.000 claims description 8
- 239000006210 lotion Substances 0.000 claims description 7
- -1 picin Proteins 0.000 claims description 7
- 235000019419 proteases Nutrition 0.000 claims description 7
- 101710130006 Beta-glucanase Proteins 0.000 claims description 4
- 102000016911 Deoxyribonucleases Human genes 0.000 claims description 4
- 108010053770 Deoxyribonucleases Proteins 0.000 claims description 4
- 239000003963 antioxidant agent Substances 0.000 claims description 4
- 230000003078 antioxidant effect Effects 0.000 claims description 4
- 238000006243 chemical reaction Methods 0.000 claims description 4
- 239000002674 ointment Substances 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 108090000317 Chymotrypsin Proteins 0.000 claims description 3
- 108090000695 Cytokines Proteins 0.000 claims description 3
- 102000004127 Cytokines Human genes 0.000 claims description 3
- 102100024295 Maltase-glucoamylase Human genes 0.000 claims description 3
- 108010028144 alpha-Glucosidases Proteins 0.000 claims description 3
- 229960002376 chymotrypsin Drugs 0.000 claims description 3
- 235000016709 nutrition Nutrition 0.000 claims description 3
- 230000035764 nutrition Effects 0.000 claims description 3
- 230000000699 topical effect Effects 0.000 claims description 3
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 claims description 2
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 claims description 2
- 108010004032 Bromelains Proteins 0.000 claims description 2
- 102100035882 Catalase Human genes 0.000 claims description 2
- 108010053835 Catalase Proteins 0.000 claims description 2
- 108010059892 Cellulase Proteins 0.000 claims description 2
- 108010022172 Chitinases Proteins 0.000 claims description 2
- 102000012286 Chitinases Human genes 0.000 claims description 2
- 108060005980 Collagenase Proteins 0.000 claims description 2
- 102000029816 Collagenase Human genes 0.000 claims description 2
- 108010046331 Deoxyribodipyrimidine photo-lyase Proteins 0.000 claims description 2
- 101710121765 Endo-1,4-beta-xylanase Proteins 0.000 claims description 2
- 108010088842 Fibrinolysin Proteins 0.000 claims description 2
- 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 claims description 2
- 102100022624 Glucoamylase Human genes 0.000 claims description 2
- 108060003951 Immunoglobulin Proteins 0.000 claims description 2
- 108010063045 Lactoferrin Proteins 0.000 claims description 2
- 102000010445 Lactoferrin Human genes 0.000 claims description 2
- 102000004882 Lipase Human genes 0.000 claims description 2
- 108090001060 Lipase Proteins 0.000 claims description 2
- 102000003792 Metallothionein Human genes 0.000 claims description 2
- 108090000157 Metallothionein Proteins 0.000 claims description 2
- 108010067372 Pancreatic elastase Proteins 0.000 claims description 2
- 102000016387 Pancreatic elastase Human genes 0.000 claims description 2
- 102000003992 Peroxidases Human genes 0.000 claims description 2
- 102000015439 Phospholipases Human genes 0.000 claims description 2
- 108010064785 Phospholipases Proteins 0.000 claims description 2
- 108010059820 Polygalacturonase Proteins 0.000 claims description 2
- 102000006382 Ribonucleases Human genes 0.000 claims description 2
- 108010083644 Ribonucleases Proteins 0.000 claims description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 claims description 2
- 108010012715 Superoxide dismutase Proteins 0.000 claims description 2
- 102000002933 Thioredoxin Human genes 0.000 claims description 2
- 108060008539 Transglutaminase Proteins 0.000 claims description 2
- 108090000631 Trypsin Proteins 0.000 claims description 2
- 102000004142 Trypsin Human genes 0.000 claims description 2
- 102000004139 alpha-Amylases Human genes 0.000 claims description 2
- 108090000637 alpha-Amylases Proteins 0.000 claims description 2
- 229940024171 alpha-amylase Drugs 0.000 claims description 2
- 230000000845 anti-microbial effect Effects 0.000 claims description 2
- 239000000427 antigen Substances 0.000 claims description 2
- 102000036639 antigens Human genes 0.000 claims description 2
- 108091007433 antigens Proteins 0.000 claims description 2
- 230000001580 bacterial effect Effects 0.000 claims description 2
- 108010047754 beta-Glucosidase Proteins 0.000 claims description 2
- 102000006995 beta-Glucosidase Human genes 0.000 claims description 2
- 235000019835 bromelain Nutrition 0.000 claims description 2
- 229940106157 cellulase Drugs 0.000 claims description 2
- 229960002424 collagenase Drugs 0.000 claims description 2
- 108010093305 exopolygalacturonase Proteins 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims description 2
- 229940088597 hormone Drugs 0.000 claims description 2
- 239000005556 hormone Substances 0.000 claims description 2
- 102000018358 immunoglobulin Human genes 0.000 claims description 2
- 229940072221 immunoglobulins Drugs 0.000 claims description 2
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 claims description 2
- 235000021242 lactoferrin Nutrition 0.000 claims description 2
- 229940078795 lactoferrin Drugs 0.000 claims description 2
- 230000000813 microbial effect Effects 0.000 claims description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 claims description 2
- 229940012957 plasmin Drugs 0.000 claims description 2
- 239000002453 shampoo Substances 0.000 claims description 2
- 239000000344 soap Substances 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 108060008226 thioredoxin Proteins 0.000 claims description 2
- 229940094937 thioredoxin Drugs 0.000 claims description 2
- 230000001256 tonic effect Effects 0.000 claims description 2
- 102000003601 transglutaminase Human genes 0.000 claims description 2
- 239000012588 trypsin Substances 0.000 claims description 2
- 229960001322 trypsin Drugs 0.000 claims description 2
- 102100026189 Beta-galactosidase Human genes 0.000 claims 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 claims 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 claims 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 1
- 108010030291 alpha-Galactosidase Proteins 0.000 claims 1
- 102000005840 alpha-Galactosidase Human genes 0.000 claims 1
- 239000004599 antimicrobial Substances 0.000 claims 1
- 108010005774 beta-Galactosidase Proteins 0.000 claims 1
- 230000000593 degrading effect Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 22
- 238000004519 manufacturing process Methods 0.000 abstract description 14
- 210000002374 sebum Anatomy 0.000 abstract description 4
- 208000002874 Acne Vulgaris Diseases 0.000 abstract description 3
- 241000894006 Bacteria Species 0.000 abstract description 3
- 241000233866 Fungi Species 0.000 abstract description 3
- 206010000496 acne Diseases 0.000 abstract description 3
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 3
- 229910021645 metal ion Inorganic materials 0.000 abstract description 3
- 230000008833 sun damage Effects 0.000 abstract description 3
- 238000012546 transfer Methods 0.000 abstract description 3
- 230000002087 whitening effect Effects 0.000 abstract description 3
- 230000037303 wrinkles Effects 0.000 abstract description 3
- 230000002265 prevention Effects 0.000 abstract 2
- 201000004384 Alopecia Diseases 0.000 abstract 1
- 230000032683 aging Effects 0.000 abstract 1
- 231100000360 alopecia Toxicity 0.000 abstract 1
- 230000003064 anti-oxidating effect Effects 0.000 abstract 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 231100000241 scar Toxicity 0.000 abstract 1
- 210000000434 stratum corneum Anatomy 0.000 abstract 1
- 239000003053 toxin Substances 0.000 abstract 1
- 231100000765 toxin Toxicity 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 37
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 22
- 230000000052 comparative effect Effects 0.000 description 19
- 238000012360 testing method Methods 0.000 description 16
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 15
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 14
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 10
- 206010015150 Erythema Diseases 0.000 description 9
- 102000035195 Peptidases Human genes 0.000 description 9
- 231100000321 erythema Toxicity 0.000 description 9
- 239000004615 ingredient Substances 0.000 description 9
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 8
- 102000011782 Keratins Human genes 0.000 description 7
- 108010076876 Keratins Proteins 0.000 description 7
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 7
- 239000007864 aqueous solution Substances 0.000 description 7
- 238000004040 coloring Methods 0.000 description 7
- 235000011187 glycerol Nutrition 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 239000003755 preservative agent Substances 0.000 description 7
- 230000002335 preservative effect Effects 0.000 description 7
- 239000008213 purified water Substances 0.000 description 7
- 239000012279 sodium borohydride Substances 0.000 description 7
- 229910000033 sodium borohydride Inorganic materials 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 206010040880 Skin irritation Diseases 0.000 description 6
- 238000000502 dialysis Methods 0.000 description 6
- 239000000049 pigment Substances 0.000 description 6
- 231100000475 skin irritation Toxicity 0.000 description 6
- 230000036556 skin irritation Effects 0.000 description 6
- 229920002307 Dextran Polymers 0.000 description 5
- 229920001214 Polysorbate 60 Polymers 0.000 description 5
- 229920002125 Sokalan® Polymers 0.000 description 5
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 5
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 5
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 5
- 229920001282 polysaccharide Polymers 0.000 description 5
- 239000005017 polysaccharide Substances 0.000 description 5
- 150000004804 polysaccharides Chemical class 0.000 description 5
- 229940113124 polysorbate 60 Drugs 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 4
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
- 239000004472 Lysine Substances 0.000 description 4
- 235000013871 bee wax Nutrition 0.000 description 4
- 239000012166 beeswax Substances 0.000 description 4
- 239000004359 castor oil Substances 0.000 description 4
- 235000019438 castor oil Nutrition 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 4
- 230000007794 irritation Effects 0.000 description 4
- 229940057995 liquid paraffin Drugs 0.000 description 4
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 4
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 4
- 229940032094 squalane Drugs 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 150000003626 triacylglycerols Chemical class 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 150000001299 aldehydes Chemical class 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 230000008472 epithelial growth Effects 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 3
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 238000000108 ultra-filtration Methods 0.000 description 3
- MLIWQXBKMZNZNF-KUHOPJCQSA-N (2e)-2,6-bis[(4-azidophenyl)methylidene]-4-methylcyclohexan-1-one Chemical compound O=C1\C(=C\C=2C=CC(=CC=2)N=[N+]=[N-])CC(C)CC1=CC1=CC=C(N=[N+]=[N-])C=C1 MLIWQXBKMZNZNF-KUHOPJCQSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 102400001368 Epidermal growth factor Human genes 0.000 description 2
- 101800003838 Epidermal growth factor Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241000872931 Myoporum sandwicense Species 0.000 description 2
- 241000966613 Sclerotinia sp. Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 229940116977 epidermal growth factor Drugs 0.000 description 2
- 238000004299 exfoliation Methods 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 229940051250 hexylene glycol Drugs 0.000 description 2
- 230000003100 immobilizing effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- GSGDTSDELPUTKU-UHFFFAOYSA-N nonoxybenzene Chemical compound CCCCCCCCCOC1=CC=CC=C1 GSGDTSDELPUTKU-UHFFFAOYSA-N 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 239000004584 polyacrylic acid Substances 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 230000003658 preventing hair loss Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- IQXJCCZJOIKIAD-UHFFFAOYSA-N 1-(2-methoxyethoxy)hexadecane Chemical compound CCCCCCCCCCCCCCCCOCCOC IQXJCCZJOIKIAD-UHFFFAOYSA-N 0.000 description 1
- 125000000972 4,5-dimethylthiazol-2-yl group Chemical group [H]C([H])([H])C1=C(N=C(*)S1)C([H])([H])[H] 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- 108090000270 Ficain Proteins 0.000 description 1
- 108010093031 Galactosidases Proteins 0.000 description 1
- 102000002464 Galactosidases Human genes 0.000 description 1
- 235000001715 Lentinula edodes Nutrition 0.000 description 1
- 240000000599 Lentinula edodes Species 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 239000002262 Schiff base Substances 0.000 description 1
- 150000004753 Schiff bases Chemical class 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910000085 borane Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 229950009789 cetomacrogol 1000 Drugs 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- MGNCLNQXLYJVJD-UHFFFAOYSA-N cyanuric chloride Chemical compound ClC1=NC(Cl)=NC(Cl)=N1 MGNCLNQXLYJVJD-UHFFFAOYSA-N 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 125000003450 decanoic acid ester group Chemical group 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 235000019836 ficin Nutrition 0.000 description 1
- POTUGHMKJGOKRI-UHFFFAOYSA-N ficin Chemical compound FI=CI=N POTUGHMKJGOKRI-UHFFFAOYSA-N 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 229920001002 functional polymer Polymers 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 230000002366 lipolytic effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- SHXOKQKTZJXHHR-UHFFFAOYSA-N n,n-diethyl-5-iminobenzo[a]phenoxazin-9-amine;hydrochloride Chemical compound [Cl-].C1=CC=C2C3=NC4=CC=C(N(CC)CC)C=C4OC3=CC(=[NH2+])C2=C1 SHXOKQKTZJXHHR-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- BARWIPMJPCRCTP-CLFAGFIQSA-N oleyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC BARWIPMJPCRCTP-CLFAGFIQSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 229920000259 polyoxyethylene lauryl ether Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 230000029983 protein stabilization Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- CEAYCPAHSNTNGO-UHFFFAOYSA-M sodium;ethane-1,2-diamine;acetate Chemical compound [Na+].CC([O-])=O.NCCN CEAYCPAHSNTNGO-UHFFFAOYSA-M 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000004043 trisaccharides Chemical class 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2462—Lysozyme (3.2.1.17)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0212—Face masks
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/66—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/02—Peptides being immobilised on, or in, an organic carrier
- C07K17/10—Peptides being immobilised on, or in, an organic carrier the carrier being a carbohydrate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6472—Cysteine endopeptidases (3.4.22)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/57—Compounds covalently linked to a(n inert) carrier molecule, e.g. conjugates, pro-fragrances
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Cosmetics (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
(단위: %) | ||||||||
제조예 1(GE-1) | 제조예 2(GE-3) | 자연상태 파파인 (0.1%) | 비교제조예 1 (0.1%) | |||||
30 ℃ | 45 ℃ | 30 ℃ | 45 ℃ | 30 ℃ | 45 ℃ | 30 ℃ | 45 ℃ | |
0일 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
10일 | 100 | 100 | 100 | 100 | 18 | 10 | 65 | 40 |
30일 | 100 | 100 | 100 | 100 | 4 | 0 | 20 | 10 |
60일 | 100 | 98 | 100 | 98 | 0 | 0 | 15 | 10 |
90일 | 100 | 95 | 100 | 95 | 0 | 0 | 14 | 9 |
(단위: %) | ||||||||
제조예 2(GE-2) | 제조예 3(GE-3) | 자연상태 리소짐 (0.1%) | 비교제조예 2 (0.1%) | |||||
30 ℃ | 45 ℃ | 30 ℃ | 45 ℃ | 30 ℃ | 45 ℃ | 30 ℃ | 45 ℃ | |
0일 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
10일 | 100 | 100 | 100 | 100 | 25 | 10 | 60 | 45 |
30일 | 100 | 100 | 100 | 100 | 9 | 5 | 22 | 12 |
60일 | 100 | 100 | 100 | 98 | 0 | 0 | 14 | 10 |
90일 | 100 | 100 | 100 | 96 | 0 | 0 | 14 | 8 |
(단위: 분해도%) | ||||
제조예 1(GE-1) | 제조예 3(GE-3) | 자연상태 파파인 | 비교제조예 1 | |
0시간 | 0 | 0 | 0 | 0 |
12시간 | 20 | 12 | 20 | 5 |
24시간 | 55 | 43 | 48 | 20 |
36시간 | 100 | 90 | 90 | 55 |
48시간 | 100 | 100 | 92 | 64 |
(단위: 홍반지수) | |||||||
대조군(증류수) | 제조예 1(GE-1) | 제조예 3(GE-3) | 자연상태 파파인 | ||||
원액 | 1/100희석 | 원액 | 1/100희석 | 원액 | 1/100희석 | ||
0일 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 |
3일 | 100.85 | 100.55 | 101.23 | 102.34 | 100.04 | 189.04 | 165.02 |
5일 | 103.58 | 103.02 | 98.56 | 98,76 | 100.05 | 225.08 | 192.78 |
7일 | 102.95 | 101.55 | 100.04 | 97.98 | 99.13 | 230.24 | 203.44 |
(단위: 생존세포 %) | |||
희석배수 | 자연상태상피세포성장인자(신규 용해) | 제조예 4(전처리) | 자연상태상피세포성장인자(전처리) |
10-2 | 121.0 | 128,2 | 88.7 |
10-3 | 126.8 | 128.9 | 94.9 |
10-4 | 124.5 | 125.4 | 102.5 |
10-5 | 112.9 | 112.8 | 101.8 |
성분 | 제형예 1 | 비교제형예 1 | 비교제형예 2 |
제조예 1의 파파인 | 0.1 | - | - |
자연상태 파파인 | - | 0.1 | - |
비교제조예 1의 파파인 | - | - | 0.1 |
글리세린 | 3.0 | 3.0 | 3.0 |
부틸렌글리콜 | 2.0 | 2.0 | 2.0 |
프로필렌글리콜 | 2.0 | 2.0 | 2.0 |
카르복시비닐폴리머 | 0.1 | 0.1 | 0.1 |
PEG-12 노닐페닐에테르 | 0.2 | 0.2 | 0.2 |
폴리솔베이트 80 | 0.4 | 0.4 | 0.4 |
에탄올 | 10.0 | 10.0 | 10.0 |
트리에탄올아민 | 0.1 | 0.1 | 0.1 |
방부제, 색소, 향료 | 적량 | 적량 | 적량 |
정제수 | to 100 | to 100 | to 100 |
(단위: %) | ||||||
제형예 1 | 비교제형예 1 | 비교제형예 2 | ||||
30 ℃ | 45 ℃ | 30 ℃ | 45 ℃ | 30 ℃ | 45 ℃ | |
0일 | 100 | 100 | 100 | 100 | 100 | 100 |
10일 | 100 | 100 | 20 | 11 | 45 | 20 |
30일 | 100 | 100 | 5 | 0 | 12 | 10 |
60일 | 100 | 100 | 0 | 0 | 4 | 0 |
90일 | 100 | 97 | 0 | 0 | 0 | 0 |
(단위: 분해도%) | |||
제형예 1 | 비교제형예 1 | 비교제형예 2 | |
0시간 | 0 | 0 | 0 |
12시간 | 24 | 22 | 0 |
24시간 | 65 | 54 | 15 |
36시간 | 100 | 80 | 35 |
48시간 | 100 | 80 | 35 |
(단위:홍반지수) | |||
대조군(증류수) | 제형예 1 | 비교제형예 1 | |
0일 | 100.00 | 100.00 | 100.00 |
3일 | 100.85 | 100.55 | 191.00 |
5일 | 107.51 | 100.02 | 225.05 |
7일 | 102.85 | 101.51 | 238.42 |
배합성분 | 중량% |
제조예 2 | 0.1 |
스쿠알란 | 5.0 |
밀납 | 4.0 |
폴리솔베이트 60 | 1.5 |
솔비탄세스퀴올레이트 | 1.5 |
유동파라핀 | 0.5 |
카프릴릭/카프릭트리글리세라이드 | 5.0 |
글리세린 | 3.0 |
부틸렌글리콜 | 3.0 |
프로필렌글리콜 | 3.0 |
카르복시비닐폴리머 | 0.1 |
트리에탄올아민 | 0.2 |
방부제, 색소, 향료 | 적량 |
정제수 | to 100 |
배합성분 | 중량% |
제조예 3 | 0.1 |
밀납 | 10.0 |
폴리솔베이트 60 | 1.5 |
PEG-60 경화피마자유 | 2.0 |
솔비탄세스퀴올레이트 | 0.5 |
유동파라핀 | 10.0 |
스쿠알란 | 5.0 |
카프릴릭/카프릭트리글리세라이드 | 5.0 |
글리세린 | 5.0 |
부틸렌글리콜 | 3.0 |
프로필렌글리콜 | 3.0 |
트리에탄올아민 | 0.2 |
방부제, 색소, 향료 | 적량 |
정제수 | to 100 |
배합성분 | 중량% |
제조예 1 | 0.1 |
밀납 | 10.0 |
폴리솔베이트 60 | 1.5 |
PEG-60 경화피마자유 | 2.0 |
솔비탄세스퀴올레이트 | 0.8 |
유동파라핀 | 40.0 |
스쿠알란 | 5.0 |
카프릴릭/카프릭트리글리세라이드 | 4.0 |
글리세린 | 5.0 |
부틸렌글리콜 | 3.0 |
프로필렌글리콜 | 3.0 |
트리에탄올아민 | 0.2 |
방부제, 색소, 향료 | 적량 |
정제수 | to 100 |
배합성분 | 중량% |
제조예 1 | 0.1 |
폴리비닐알콜 | 13.0 |
소듐카르복시메틸셀룰로오스 | 0.2 |
글리세린 | 5.0 |
알란토인 | 0.1 |
에탄올 | 6.0 |
PEG-12 노닐페닐에테르 | 0.3 |
폴리솔베이트 60 | 0.3 |
방부제, 색소, 향료 | 적량 |
정제수 | to 100 |
배합성분 | 중량% |
제조예 2 | 0.1 |
에틸렌디아민초산나트륨 | 0.05 |
글리세린 | 5.0 |
카르복시비닐폴리머 | 0.3 |
에탄올 | 5.0 |
PEG-60 경화피마자유 | 0.5 |
트리에탄올아민 | 0.3 |
방부제, 색소, 향료 | 적량 |
정제수 | to 100 |
배합성분 | 중량% |
제조예 4 | 1.0 |
밀납 | 10 |
폴리솔베이트 60 | 5.0 |
PEG-60 경화피마자유 | 2.0 |
솔비탄세스퀴올레이트 | 0.5 |
바셀린 | 5.0 |
유동파라핀 | 10.0 |
스쿠알란 | 5.0 |
쉐어버터 | 3.0 |
카프릴릭/카프릭트리글리세라이드 | 5.0 |
글리세린 | 10.0 |
프로필렌글리콜 | 10.2 |
트리에탄올아민 | 0.2 |
방부제, 색소, 향료 | 적량 |
정제수 | to 100 |
배합성분 | 중량% |
제조예 4 | 3.0 |
폴리아크릴산(Carbopol 940) | 1.5 |
이소프로판올 | 5.0 |
헥실렌글리콜 | 25.0 |
트리에탄올아민 | 1.7 |
탈이온수 | to 100 |
배합성분 | 중량% |
제조예 4 | 1.2 |
헥실렌글리콜 | 20.0 |
디에틸아민 | 0.7 |
폴리아크릴산(Carbopol 934P) | 1.0 |
아황산나트륨 | 0.1 |
폴리옥시에틸렌라우릴에테르(E.O=9) | 1.0 |
폴리히드록시에틸렌세틸스테아릴에테르(Cetomacrogol 1000) | 1.0 |
점성의 파라핀 오일 | 2.5 |
카프릴산에스테르/카프르산에스테르(Cetiol LC) | 2.5 |
폴리에틸렌글리콜 400 | 3.0 |
탈이온수 | to 100 |
Claims (9)
- 효소 또는 단백질을 안정화시키는 방법에 있어서, 안정화제로 베타-1,3-글루칸 주당쇄에 베타-1,6-잔기를 갖는 글루칸을 사용함을 특징으로 하는 효소 또는 단백질의 안정화 방법.
- 제 1항에 있어서, 상기 효소 또는 단백질을 안정화시키는 방법은(1) 베타-1,3-글루칸 주당쇄에 베타-1,6-잔기를 갖는 글루칸을 과요오드산염류와 반응시키는 단계;(2) 상기 (1)단계 반응액의 잔류 과요오드산염류를 제거하는 단계;(3) 상기 (2)단계의 용액에 효소 또는 단백질을 0.00001∼10.0중량%의 양으로 첨가하는 단계;(4) 상기 (3)단계의 용액에 0.0001∼1.0중량%의 환원제를 첨가하는 단계; 및(5) 상기 (4)단계의 용액을 세척하는 단계;를 포함함을 특징으로 하는 방법.
- 제 1항 또는 제 2항에 있어서, 상기 효소는 파파인(papain), 브로멜라인(bromelein), 피신(ficin), 트립신(trypsin), 키모트립신(chymotrypsin), 콜라게나제(collagenase), 엘라스테제(elastase), 플라스민(plasmin), 세균성 프로테아제(bactrial protease), α-아밀라제(amylase), 글루코아밀라제(glucoamylase), 셀룰라제(cellulase), 펙티나제(pectinase), 키실라나제(xylanase), α-글루코시다제(glucosidase), β-글루코시다제, α-갈락톡시다제(galactosidase), β-갈락톡시다제, β-글루카나제(glucanase), 키티나아제(chitinase), 만난분해효소(mannannase) , 포스포리파제(phospholipase), 트리아실글리세롤분해효소(triacylglycerol hydrolase), 데옥시리보핵산분해효소(DNAase), 리보핵산분해효소(RNAase), 인산분해효소류(phosphatase), 리소짐(lysozyme), 카탈라제(catalase), 과산화물 디스뮤테이즈(superoxide dismutase), 트랜스글루타미나아제(transglutaminase), 퍼옥시다제(peroxidase), 포토리아제(photolyase) 및 미생물 유래 복합효소류로 이루어진 군에서 선택된 1종 이상의 효소, 이들의 결합체 또는 이들의 펩타이드, 당 및 지방 복합체이고, 상기 단백질은 사이토카인류(cytokines), 세포성장인자류(growth factors), 호르몬류(hormones), 항원(antigen) 및 항체(antibody), 면역글로블린(immunoglobulins), 락토페린(lactoferrin), 메탈로티오네인(metallothionein), 티오레독신(thioredoxin), 항균성 단백질 및 항산화 단백질로 이루어진 군에서 선택된 1종 이상의 단백질, 이들의 결합체 또는 이들의 펩타이드, 당 및 지방 복합체임을 특징으로 하는 방법.
- 제 1항 또는 제 2항에 있어서, 상기 베타-1,3-글루칸 주당쇄에 베타-1,6-잔기를 갖는 글루칸은 스키조필란(schizophyllan), 스클레로글루칸(scleroglucan) 또는 렌티난(lentinan)임을 특징으로 하는 방법.
- 제 4항에 있어서, 상기 베타-1,3-글루칸 주당쇄에 베타-1,6-잔기를 갖는 글루칸은 마이크로플루이다이저(microfluidizer), 초음파분쇄기(sonicator) 또는 베타-글루카나제(β-glucanase)를 사용하여 분자량을 변형시킨 것임을 특징으로 하는 방법.
- 제 2항에 있어서, 상기 효소 또는 단백질이 2종 이상인 경우, 효소 또는 단백질 중에 하나를 상기 (3)단계에서 먼저 첨가한 후, 나머지 효소 또는 단백질은 상기 (4)단계에서 첨가함을 특징으로 하는 방법.
- 제 1항 또는 제 2항에 기재된 방법에 의해 안정화된 효소 또는 단백질을 조성물 총 중량에 대하여 0.00001∼100중량%의 양으로 함유함을 특징으로 하는 외용제 조성물.
- 제 7항에 있어서, 상기 외용제 조성물은 유연화장수, 영양화장수, 마사지크림, 영양크림, 메이컵 베이스, 립스틱, 팩, 젤, 샴푸, 린스, 헤어토닉 또는 비누의 제형을 갖는 화장료 조성물임을 특징으로 하는 외용제 조성물.
- 제 7항에 있어서, 상기 외용제 조성물은 로션, 연고, 겔, 크림, 패취 또는 분무제의 경피투여형 제형을 가짐을 특징으로 외용제 조성물.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1019990009380A KR100283848B1 (ko) | 1999-03-19 | 1999-03-19 | 안정화된 효소 또는 단백질을 제조하는 방법 및 이에 의해 제공되는 안정화 효소 또는 단백질을 함유하는 외용제 조성물 |
JP33876599A JP4077126B2 (ja) | 1999-03-19 | 1999-11-29 | 変性蛋白質及びこの製造方法並びにこの変性蛋白質を含有する外用剤組成物 |
FR9915067A FR2791059B1 (fr) | 1999-03-19 | 1999-11-30 | Proteine modifiee, procede de preparation de celle-ci et compositions pour une application externe contenant la proteine modifiee |
US09/453,965 US6406897B1 (en) | 1999-03-19 | 1999-12-03 | Modified protein, method for preparation thereof and compositions for external application containing the modified protein |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1019990009380A KR100283848B1 (ko) | 1999-03-19 | 1999-03-19 | 안정화된 효소 또는 단백질을 제조하는 방법 및 이에 의해 제공되는 안정화 효소 또는 단백질을 함유하는 외용제 조성물 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20000060771A true KR20000060771A (ko) | 2000-10-16 |
KR100283848B1 KR100283848B1 (ko) | 2001-02-15 |
Family
ID=19577056
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019990009380A KR100283848B1 (ko) | 1999-03-19 | 1999-03-19 | 안정화된 효소 또는 단백질을 제조하는 방법 및 이에 의해 제공되는 안정화 효소 또는 단백질을 함유하는 외용제 조성물 |
Country Status (4)
Country | Link |
---|---|
US (1) | US6406897B1 (ko) |
JP (1) | JP4077126B2 (ko) |
KR (1) | KR100283848B1 (ko) |
FR (1) | FR2791059B1 (ko) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001087255A1 (en) * | 2000-05-16 | 2001-11-22 | Pacific Corporation | External application for enhancing the skin permeability of the active components therein |
KR20030055442A (ko) * | 2001-12-26 | 2003-07-04 | 주식회사 참 존 | 다당체를 이용한 안정화 효소의 제조방법 및 이들 안정화효소가 첨가된 조성물 |
KR100447055B1 (ko) * | 2001-07-30 | 2004-09-04 | 주식회사 참 존 | 변성 알터난의 제조방법 및 이를 이용한 효소 안정화 방법 |
KR100507960B1 (ko) * | 2002-10-22 | 2005-08-19 | (주)나노팜 | 피부 각질 제거용 조성물, 이의 제조방법, 및 이를 포함하는 세안조성물 |
KR100654063B1 (ko) * | 2005-08-11 | 2006-12-06 | 주식회사 코리아나화장품 | 베타-1,6-분지-베타-1,3-글루칸을 포접하여 안정화한나노리포좀을 유효성분으로 함유하는 피부노화 방지용화장료 조성물 |
KR20170116279A (ko) * | 2016-04-08 | 2017-10-19 | 주식회사 마크로케어 | 분리형 화장료 제형 |
CN110090170A (zh) * | 2018-06-26 | 2019-08-06 | 浙江立恩生物科技有限公司 | 具有生发固发防脱的生物多糖及其应用 |
WO2023172070A1 (ko) * | 2022-03-08 | 2023-09-14 | 주식회사 코넥스트 | 콜라게네이즈, 칼슘, 히스티딘 및 글리신을 포함하는 조성물 및 콜라게네이즈의 안정화 방법 |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100499564B1 (ko) * | 2003-03-28 | 2005-07-07 | 신석봉 | 모발의 재생방법 및 발모제 조성물 |
JP2008505853A (ja) | 2004-04-13 | 2008-02-28 | クインテセンス バイオサイエンシーズ インコーポレーティッド | 細胞傷害性薬剤としての非天然のリボヌクレアーゼ複合体 |
JP4195486B2 (ja) * | 2004-08-10 | 2008-12-10 | 株式会社Nrlファーマ | ラクトフェリン複合体及びその製造方法 |
US7709001B2 (en) * | 2005-04-08 | 2010-05-04 | Wyeth Llc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
US8840882B2 (en) * | 2006-06-23 | 2014-09-23 | Quintessence Biosciences, Inc. | Modified ribonucleases |
US8298801B2 (en) | 2006-07-17 | 2012-10-30 | Quintessence Biosciences, Inc. | Methods and compositions for the treatment of cancer |
US20080160043A1 (en) * | 2007-07-16 | 2008-07-03 | Kim Moo-Sung | Preparation method of beta-glucan from schizophyllum commune and composition for external application comprising the same |
US8697062B2 (en) * | 2007-10-08 | 2014-04-15 | Quintessence Biosciences, Inc. | Compositions and methods for ribonuclease-based therapeutics |
US8246992B2 (en) | 2007-11-01 | 2012-08-21 | Osaka City University | β-1,3-glucan-derived polyaldehyde/polyamine hydrogel |
BRPI0920743A2 (pt) | 2008-10-01 | 2016-09-20 | Quintessence Biosciences Inc | ribonucleases terapeuticas |
CA2829042A1 (en) * | 2011-03-29 | 2012-10-04 | Basf Se | Method for the coating of a cellulose material by using a glucan |
US8852750B2 (en) | 2011-03-29 | 2014-10-07 | Wintershall Holding GmbH | Method for the coating of a cellulose material by using a glucan |
WO2013062054A1 (ja) * | 2011-10-28 | 2013-05-02 | サンスター技研株式会社 | 組成物およびその製造方法 |
WO2015118789A1 (ja) * | 2014-02-06 | 2015-08-13 | 独立行政法人科学技術振興機構 | ペプチド/β-1,3-グルカン複合体及びその製造方法並びにそれを含む医薬組成物 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4556554A (en) | 1981-06-01 | 1985-12-03 | Germaine Monteil Cosmetiques Corp. | Immobilized enzymes |
US5116612A (en) * | 1987-06-23 | 1992-05-26 | Allergy Immuno Technologies, Inc. | Immunotherapy agents for treatment of IgE mediated allergies |
US5230891A (en) | 1990-08-20 | 1993-07-27 | Kanebo Limited | Modified protease, method of producing the same and cosmetic products containing the modified protease |
JP2922278B2 (ja) * | 1990-10-02 | 1999-07-19 | 協和メデックス株式会社 | 成分分析用試薬組成物 |
EP0595209A3 (en) * | 1992-10-23 | 1996-07-17 | R I T A Corp An Illinois Corp | Cosmetic composition |
US5821343A (en) * | 1996-04-25 | 1998-10-13 | Medtronic Inc | Oxidative method for attachment of biomolecules to surfaces of medical devices |
-
1999
- 1999-03-19 KR KR1019990009380A patent/KR100283848B1/ko not_active IP Right Cessation
- 1999-11-29 JP JP33876599A patent/JP4077126B2/ja not_active Expired - Fee Related
- 1999-11-30 FR FR9915067A patent/FR2791059B1/fr not_active Expired - Lifetime
- 1999-12-03 US US09/453,965 patent/US6406897B1/en not_active Expired - Fee Related
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001087255A1 (en) * | 2000-05-16 | 2001-11-22 | Pacific Corporation | External application for enhancing the skin permeability of the active components therein |
KR100447055B1 (ko) * | 2001-07-30 | 2004-09-04 | 주식회사 참 존 | 변성 알터난의 제조방법 및 이를 이용한 효소 안정화 방법 |
KR20030055442A (ko) * | 2001-12-26 | 2003-07-04 | 주식회사 참 존 | 다당체를 이용한 안정화 효소의 제조방법 및 이들 안정화효소가 첨가된 조성물 |
KR100507960B1 (ko) * | 2002-10-22 | 2005-08-19 | (주)나노팜 | 피부 각질 제거용 조성물, 이의 제조방법, 및 이를 포함하는 세안조성물 |
KR100654063B1 (ko) * | 2005-08-11 | 2006-12-06 | 주식회사 코리아나화장품 | 베타-1,6-분지-베타-1,3-글루칸을 포접하여 안정화한나노리포좀을 유효성분으로 함유하는 피부노화 방지용화장료 조성물 |
KR20170116279A (ko) * | 2016-04-08 | 2017-10-19 | 주식회사 마크로케어 | 분리형 화장료 제형 |
CN110090170A (zh) * | 2018-06-26 | 2019-08-06 | 浙江立恩生物科技有限公司 | 具有生发固发防脱的生物多糖及其应用 |
CN110090170B (zh) * | 2018-06-26 | 2022-06-28 | 浙江立恩生物科技有限公司 | 具有生发固发防脱的生物多糖及其应用 |
WO2023172070A1 (ko) * | 2022-03-08 | 2023-09-14 | 주식회사 코넥스트 | 콜라게네이즈, 칼슘, 히스티딘 및 글리신을 포함하는 조성물 및 콜라게네이즈의 안정화 방법 |
Also Published As
Publication number | Publication date |
---|---|
US6406897B1 (en) | 2002-06-18 |
FR2791059B1 (fr) | 2005-04-01 |
FR2791059A1 (fr) | 2000-09-22 |
JP4077126B2 (ja) | 2008-04-16 |
JP2000273182A (ja) | 2000-10-03 |
KR100283848B1 (ko) | 2001-02-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100283848B1 (ko) | 안정화된 효소 또는 단백질을 제조하는 방법 및 이에 의해 제공되는 안정화 효소 또는 단백질을 함유하는 외용제 조성물 | |
KR100628413B1 (ko) | 폴리감마글루탐산―비타민c 복합체를 함유하는 콜라게나제저해제 및 그 용도 | |
US5980916A (en) | Use of laminarin and oligosaccharides derived therefrom in cosmetics and for preparing a skin treatment drug | |
US6689349B1 (en) | Skin protection agents containing a fragment mixture produced from hyaluronic acid by hydrolysis | |
CN101172095A (zh) | 含有蜂王浆的蛋白水解物的化妆材料 | |
FR2997304A1 (fr) | Utilisation d’un extrait de lin, en tant qu’agent actif activateur de la synthese de peptides antimicrobiens | |
EP1282393B1 (en) | External application for enhancing the skin permeability of the active components therein | |
WO2013160349A2 (en) | Cosmetic composition comprising a phosphorylated oligosaccharide and a polysaccharide | |
KR100389983B1 (ko) | 알부틴과 글루코시다제를 유효 성분으로 하는 미백제 | |
JPH05271049A (ja) | 皮膚化粧料 | |
KR20060020630A (ko) | 피지 관련 피부 질환의 국소 치료방법 | |
KR100328877B1 (ko) | 베타-1, 6-분지-베타-1, 3-글루칸을 함유하는 항염증 및피부자극 완화효과를 갖는 외용제 조성물 | |
KR101587077B1 (ko) | 피부 생리활성을 가지는 백년초 발효물을 포함하는 조성물 | |
KR20200000243A (ko) | 베타글루칸, 글리시틴 및 4',6,7-트리메톡시이소플라본을 포함하는 창상 치료 또는 피부 활성용 약학적 조성물 | |
KR20190047582A (ko) | 식물성 소재의 2단계 순차적 효소처리 추출물과 이를 포함하는 기능성 화장료 조성물 및 그 제조방법 | |
GB2443036A (en) | Composition for controlling FGF-2-related skin alteration | |
JP5705397B2 (ja) | FGF−2またはFGF−β増殖因子を保護するための物質の使用 | |
KR20090020002A (ko) | 효소 또는 단백질의 안정화 방법 및 이에 의해 제공되는효소를 함유하는 외용제 조성물 | |
KR100585613B1 (ko) | 베타-1,3-글루칸과 인삼사포닌을 함유하는 피부 외용제조성물 | |
US20080089906A1 (en) | Use of substances to protect FGF-2 or FGF-beta growth factor | |
JPH07188045A (ja) | 抗プラスミン剤 | |
JP2834278B2 (ja) | 化粧料及び皮膚外用剤 | |
CN111840193A (zh) | 一种可提高皮肤吸收率的护肤膏 | |
RU2096032C1 (ru) | Косметическое средство | |
CN114796046B (zh) | 一种美白淡斑抗氧化组合物及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20121127 Year of fee payment: 13 |
|
FPAY | Annual fee payment |
Payment date: 20131121 Year of fee payment: 14 |
|
FPAY | Annual fee payment |
Payment date: 20141120 Year of fee payment: 15 |
|
FPAY | Annual fee payment |
Payment date: 20151130 Year of fee payment: 16 |
|
FPAY | Annual fee payment |
Payment date: 20161010 Year of fee payment: 17 |
|
FPAY | Annual fee payment |
Payment date: 20170928 Year of fee payment: 18 |
|
FPAY | Annual fee payment |
Payment date: 20181002 Year of fee payment: 19 |
|
EXPY | Expiration of term |